- Home
- Products
- Customized ADCs
- IL6
- Anti-IL6 (Elsilimomab)-MC-Vc-PAB-MMAE ADC
Anti-IL6 (Elsilimomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1439)
This ADC product is comprised of an anti-IL6 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL6
- Alternative Names
- IL6; interleukin 6 (interferon, beta 2); IFNB2; interleukin-6; BSF2; HGF; HSF; IL 6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor; IL-6;
- Target Entrez Gene ID
- 3569
- Target UniProt ID
- P05231
- Overview
- This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. Alternative splicing results in multiple transcript variants.
- Overview
- Humanized Anti-IL6 IgG1 antibody, Elsilimomab
- Generic name
- Elsilimomab
- Host animal
- Mouse
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD38 (Daratumumab)-SPDB-DM4 ADC (CAT#: ADC-W-825)
- Anti-HLA-DRB1 (Apolizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1206)
- Anti-VEGFA (Bevacizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1931)
- Anti-RTN4 (Atinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1741)
- Anti-CD4 (Priliximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-864)
- Anti-ICAM1 (Enlimomab)-SMCC-DM1 ADC (CAT#: ADC-W-1208)
- Anti-IL2RA (Daclizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1373)
- Anti-TNF (Golimumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1824)
- Anti-VEGFA (Bevacizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1933)
- Anti-PDGFR (Olaratumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1711)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1439. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Linker
Same Payload
Same Target
CAT# | Product Name | Linker | Payload |
ADC-W-2586 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2607 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2624 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2602 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2614 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
CAT# | Product Name | Linker | Payload |
ADC-W-2623 | Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2557 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2568 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2574 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-1434 | Anti-IL6-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2250 | Anti-IL6 (Enlimomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2246 | Anti-IL6 (Enlimomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2247 | Anti-IL6 (Enlimomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1435 | Anti-IL6-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.